US-based CorMatrix Cardiovascular has treated the patient using its CorMatrix Tyke, which is designed to repair cardiac tissues in neonates and infants.

In February, the US Food and Drug Administration (FDA) granted 510(k) clearance for CorMatrix Tyke.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It can be applied on infants to repair pericardial structures, which acts as an epicardial covering for damaged or repaired cardiac structures.

The product acts similar to patch material for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair.

"The availability of Tyke and its two ply construction will allow us the ability to repair the tiniest structures in the most delicate and tiniest of newborn babies."

Tyke is composed of two layers of CorMatrix ECM when compared to the existing CorMatrix ECM for Cardiac Tissue Repair with four layers.

See Also:

The new product with its thinner texture is applicable for smaller repairs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pediatric and congenital heart surgery and surgical director, pediatric heart transplant chief Dr Frank Scholl said: "The availability of Tyke and its two ply construction will allow us the ability to repair the tiniest structures in the most delicate and tiniest of newborn babies, and achieve a more accurate and hopefully more durable repair.

"We are excited about the future Tyke provides for our most fragile patients."

According to the American Academy of Pediatrics and the Congenital Heart Public Health Consortium (CHPHC), congenital heart defects are most commonly occurring birth defects.

Approximately 40,000 babies are born with the congenital heart defect in the US.

CorMatrix president and CEO Andrew Green said: "CorMatrix Tyke is one of the few products commercially available that is specifically designed and labelled for the treatment of neonate and infant cardiac tissue repair."